Quantinno Capital Management LP Buys 16,928 Shares of Jazz Pharmaceuticals PLC $JAZZ

Quantinno Capital Management LP raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 191,286 shares of the specialty pharmaceutical company’s stock after acquiring an additional 16,928 shares during the quarter. Quantinno Capital Management LP’s holdings in Jazz Pharmaceuticals were worth $36,163,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of JAZZ. Capital World Investors lifted its position in shares of Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after purchasing an additional 111,735 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after purchasing an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its position in Jazz Pharmaceuticals by 3.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock worth $285,113,000 after purchasing an additional 50,996 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on JAZZ shares. Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. TD Cowen upped their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Truist Financial decreased their price target on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.06.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the transaction, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This trade represents a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 0.9%

Shares of Jazz Pharmaceuticals stock opened at $258.38 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $261.30. The business has a fifty day simple moving average of $239.00 and a 200 day simple moving average of $206.04. The stock has a market cap of $16.23 billion, a PE ratio of -12,912.54, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion during the quarter. Research analysts predict that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.